eFFECTOR Therapeutics Aktie Logo
US28202V1089
A3CY8W
EFTR

eFFECTOR Therapeutics Aktie

Loading quotes...

Forecast

The analysts' average price target is €4.99 (+687,227.82%). The median is €4.99 (+687,227.82%).

Buy
  6
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, eFFECTOR Therapeutics Aktie had revenue of €0 and net profit of -€32.39M
(EUR) 2023
YoY
Revenue 0 100.00%
Gross profit -100.41K 103.08%
Net profit -32.39M 168.81%
EBITDA -29.65M 56.22%

Fundamentals

Metric Value
Market capitalization
€3.42K
Number of shares
4.71M
52-week high/low
€0.0181 - €0.000181
Dividends No
Beta
2.48
P/E ratio
0.00
PEG ratio
0.00
P/B ratio
0.00
P/S ratio
0.00

Company profile

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Name
eFFECTOR Therapeutics Aktie
CEO
Craig R. Jalbert
Headquarters Solana Beach, ca
USA
Website
Sector
Materials
Industry
Chemicals
IPO
03/01/2021
Employees 14

Ticker symbols

Exchange Symbol
NASDAQ
EFTR
Frankfurt
LWK1.F
München
LWK1.MU
🍪

Parqet  uses cookies. Learn more